• Home
  • About Us
  • Blog

Pulmonary Hypertension RN

  • What is Pulmonary Hypertension?
    • What is Pulmonary Hypertension?
    • Pulmonary Hypertension Symptoms
    • Types of Pulmonary Hypertension
    • Causes of Pulmonary Hypertension
    • PH vs. PAH
    • Diastolic Heart Failure vs. PAH
    • WHO Group 3 Pulmonary Hypertension, IPF & COPD
    • Pulmonary Veno-Occlusive Disease
    • Hereditary Hemorrhagic Telangiectasia (HHT)
      • Hereditary Hemorrhagic Telangiectasia (HHT) Treatment
    • Functional Classification of Pulmonary Hypertension
    • Congenital Heart Disease
      • Eisenmenger’s Syndrome
      • Update on Management of PAH-CHD
      • Congenital Heart Disease & Sleep Apnea
      • Complex Congenital Heart Disease
      • Atrial Septal Defect and Pulmonary Arterial Hypertension
    • Pediatric Pulmonary Arterial Hypertension
    • Sickle Cell and Pulmonary Hypertension
    • Stimulant Associated Pulmonary Arterial Hypertension
    • Porto-Pulmonary Syndrome
    • Research, Life Expectancy & Prognosis for PH
  • Diagnosing & Monitoring PAH
    • Pulmonary Arterial Hypertension Diagnosis
    • How Am I Doing? Assessing Your PAH.
    • Blood Tests
    • Cardiopulmonary Exercise Test (CPET)
    • CT (Computed Tomography) Scan
    • Echocardiogram: An Overview
    • Echocardiogram: A Detailed Look
    • Pulmonary Function Tests (PFTs)
    • Right Heart Catheterization
    • Six Minute Walk
    • Ventilation Perfusion Scan (VQ Scan)
    • CTEPH
      • CTEPH: WHO Group 4 Pulmonary Hypertension
      • PTE (Pulmonary Thromboendarterectomy) Surgery
      • Adempas used to Treat PAH and CTEPH
  • PAH Treatment
    • Sotatercept (Winrevair) Approved
    • Pulmonary Hypertension Centers
    • Pulmonary Hypertension Treatments
    • Continuously Infused Therapies Used to Treat PH
    • Prostanoids for Treatment of PH
    • Adcirca and Revatio Used to Treat Pulmonary Arterial Hypertension (PAH)
    • Adempas used to Treat PAH and CTEPH
    • Tracleer, Letairis, and Opsumit Treatments
    • Oxygen Therapy for Pulmonary Hypertension
    • Salt and Water Restrictions
    • Exercise & PAH
    • Diuretics
    • Blood Thinners
    • Getting the Most Out of PAH Therapy
      • Letairis
      • Opsumit
      • Sildenafil (Revatio)
  • Research
  • FAQ’s
    • Implanted Remodulin Pump, Right Heart Catheterization, PAH & Pregnancy
    • Oral Treatments, Care Centers & Hole in Heart
    • FAQ’s: Altitude, Cold & Allergy Medications
    • FAQ’s: Psoriasis, Idiopathic PAH, Contraceptives & PAH
    • FAQ’s: Causes of Pulmonary Hypertension, Symptom Frequency & Care Centers
    • FAQ: PAH Experts, Pregnancy, Mild PAH & Vacationing
    • FAQ’s: CTEPH, Blood Clots, Corrective Surgery & PAH Care Centers
    • FAQ’s: VQ Scans & PAH Curable?
    • FAQ’s: Mild Pulmonary Hypertension?
    • FAQ’s: Boating, Swimming & Eating with PAH
    • FAQ’s: Borderline Pulmonary Hypertension, Hand Swelling, Children with PAH, Costs

Update on the Implanted Remodulin Pump

April 10, 2017 By Dr. Jeremy Feldman

update

This week we learned that the much-awaited arrival of the Implanted Pump System for Remodulin would be further delayed.  The FDA did not grant Medtronic and United Therapeutics approval.  Details are scant but the announcement indicated that the device might be approved in the beginning of 2018. PAH Patients and doctors alike were let down by the delay.  The delay does not … [Read more...]

Update on Caring Voice Coalition: January 13, 2017

January 13, 2017 By Dr. Jeremy Feldman

update

Caring Voice Coalition will reopen for grant applications on Monday January 16th at 9am Eastern time.  Patients who have yet to receive grant support should call and keep calling. You should also try and connect with Caring Voice by email and on their website. We have had encouraging news from several of the drug manufacturers that they are working with the federal … [Read more...]

Looking Back at 2016 in PAH

December 29, 2016 By Dr. Jeremy Feldman

2016 in PAH Treatments

2016 has been a busy year for PAH.  There was exciting progress and some disappointment as well.  Reata Pharmaceuticals launched their phase 3 study of Bardoxylone Methyl in connective tissue disease related PAH (The CATALYST Study) after showing promising results in their phase 2 study.  Actelion has started their phase 4 study (TRITON) comparing triple vs double up-front … [Read more...]

Update on Affording Your PAH Medications

December 7, 2016 By Dr. Jeremy Feldman

Update on PAH Treatments

There is good news and bad news.  Let’s get the bad news out of the way first.  Good Days announced that they have no further funding available for 2017 for PAH patients.  Now the good news - Caring Voices announced that they will reopen their funding for 2017 beginning Thursday December 8th in the morning.  It is unclear how long they will remain open and how many patients … [Read more...]

Update on Caring Voices for PAH Meds

December 1, 2016 By Dr. Jeremy Feldman

Update on PAH Treatments

We received notification today that Caring Voices has closed their 2017 roster of patients that they are able to help for the time being.  Very little guidance was given about what this means for the remainder of 2017.  There is a possibility that they will reopen their roster and be able to expand the number of PAH patients that they help. Unfortunately this has left … [Read more...]

« Previous Page
Next Page »

PAH Life Expectancy

PAH Research

Research, Life Expectancy & Prognosis for PH

Major Developments in Pulmonary Hypertension Affecting Prognosis 1.     Approval of

Where to Get Treatment?

CCCs for PAH

Pulmonary Hypertension Centers

Where to get treatment for pulmonary hypertension? Pulmonary arterial hypertension is a

Popular Posts

Decrease the stress of moving

5 Steps For Making Moving with PAH Less Stressful

By Dr. Jeremy Feldman

Moving can be both exciting and stressful for everyone. Finding a new place to live, learning a new neighborhood,

update

Update on Caring Voice Coalition: January 13, 2017

By Dr. Jeremy Feldman

Caring Voice Coalition will reopen for grant applications on Monday January 16th at 9am Eastern time.  Patients who have

good news in pah

 

Disclaimer

Recent Blog Posts

  • Making Order from Chaos October 26, 2025
  • Sotatercept: ZENITH and HYPERION Trials June 22, 2025
  • In Memoriam:  Greg Ahearn, MD June 16, 2024

Categories

Archives